Clinical trials: Leukemia-Lymphoma, open to volunteers
Acute Lymphoblastic Leukemia, Adult
RWE of Pediatric-like Protocol for AYA Patients With Ph-negative ALL
This is a multicenter, observational real world clinical trial with prospective follow up that will evaluate the treatment outcome of adolescent and young patients with ph-negative acute lymphoblastic leukemia with first-line…
- Trial name
- NCT05127148
- Testing
- Evaluation of survival and toxicities in AYA Ph-negative ALL patients treating in first line depending on risk category.
- Where
- 2 sites in Argentina
- Volunteers
- 100 people
- Sponsor
- Grupo Argentino de Tratamiento de la Leucemia Aguda
Lymphoma, Chemotherapy-induced Neutropenia
Danish Elder Lymphoma Patient Hematopoietic Investigation
Every year approximately 300 Danish patients die from lymphoma. The median age at diagnosis is 70 years. Lymphoma can be efficiently treated with chemotherapy, and potentially cured.
- Conditions
- Lymphoma, Chemotherapy-induced Neutropenia, Chemotherapy-Related Leukemia, Chemotherapeutic Toxicity
- Trial name
- DELPHI (NCT05245487)
- Testing
- DNA repair gene mutation analysis
- Where
- Denmark
- Volunteers
- 300 people
- Sponsor
- Copenhagen University Hospital, Rigshospitalet
Lymphoblastic Leukemia, Philadelphia-Positive ALL
Treatment Protocol for Newky Diagnosed Adult Ph Positive ALL
The goal of this prospective, multicenter, open observational study is to assess the efficacy and safety of the treatment for acute lymphoblastic leukemia Ph' positive adult patients with approved combinations of chemotherapy and…
- Conditions
- Lymphoblastic Leukemia, Philadelphia-Positive ALL, Adult ALL
- Trial name
- LALPh2022 (NCT06175702)
- Testing
- Vincristine, Dexamethasone, Imatinib
- Volunteers
- 150 people
- Sponsor
- PETHEMA Foundation
Autoimmune Hemolytic Anemia, Chronic Lymphocytic Leukemia
Ibrutinib for the Treatment of AIHA in Patients With CLL/SLL or CLL-like MBL
This is a multicenter, single arm, phase II study aimed at evaluating ibrutinib therapy for the treatment of AIHA in patients with CLL/SLL or CLL-like MBL.
- Conditions
- Autoimmune Hemolytic Anemia, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Monoclonal B-Cell Lymphocytosis CLL-Type
- Trial name
- NCT05694312
- Testing
- Ibrutinib 420 mg
- Where
- 3 sites in Italy
- Volunteers
- 45 people
- Sponsor
- Gruppo Italiano Malattie EMatologiche dell'Adulto
T-lymphoblastic Lymphoma, T-ALL
CD7 CAR-T in Adults With Relapsed or Refractory T-LBL/ALL Clinical Study
To evaluate the tolerability and safety of SENL101 in patients with relapsed or refractory T-LBL/ALL.
- Trial name
- NCT06136364
- Testing
- CAR-T
- Where
- China
- Volunteers
- 9 people
- Sponsor
- Hebei Senlang Biotechnology Inc., Ltd.
Breast Cancer Female, Acute Leukemia
Use of GnRHa During Chemotherapy for Fertility Protection
Many cytotoxic drugs may harm the fertility of young women treated for cancer. The aim of the study is to investigate if the Gonadotropin-Releasing Hormone agonist (GnRHa) during cancer treatment can preserve the fertility of…
- Conditions
- Breast Cancer Female, Acute Leukemia, Lymphoma, Osteosarcoma
- Trial name
- ProFertil (NCT05328258)
- Testing
- Triptorelin Embonate, Sodium Chloride solution 0.9%
- Where
- 17 sites in Sweden
- Volunteers
- 500 people
- Sponsor
- Kenny Rodriguez-Wallberg
Follicular Lymphoma, Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
(CHANT)Real World Study of Duvelisib in the Treatment of Non-Hodgkin's Lymphoma (NHL)
This is a multicenter, non-interventional and prospective real-world study to evaluate the efficacy and safety of Duvelisib capsules in patients with non-Hodgkin's lymphoma.
- Conditions
- Follicular Lymphoma, Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Richter Syndrome, Marginal Zone Lymphoma
- Trial name
- NCT05923502
- Testing
- Duvelisib
- Volunteers
- 200 people
- Sponsor
- Ruijin Hospital
B-cell Acute Lymphoblastic Leukemia, B-cell Lymphoma
CD19/CD22 Bispecific CAR-T Cell Therapy for Relapsed/Refractory B-cell Lymphoma or Acute Lymphoblastic Leukemia
CAR-T cell therapy targeting CD19 has been shown to be effective in heavily-pretreated B-cell ALL or NHL, but relapses post-CAR-T are common, and CD19 antigen loss is one of the reasons.
- Conditions
- B-cell Acute Lymphoblastic Leukemia, B-cell Lymphoma, Diffuse Large B Cell Lymphoma
- Trial name
- NCT06081478
- Testing
- CD19/CD22-bispecific CAR-T cells
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Beijing Tongren Hospital
Chemotherapy-Related Cognitive Impairment, Chemotherapeutic Toxicity
Investigating Cognitive Impairment in Young Patients With Cancer Prospectively
The MyBrain study investigates the brain function of children, adolescents and young adults during and after chemo treatment for cancer.
- Conditions
- Chemotherapy-Related Cognitive Impairment, Chemotherapeutic Toxicity, Chemo-brain, Cancer
- Trial name
- MyBrain (NCT05840575)
- Where
- Denmark
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Copenhagen University Hospital, Rigshospitalet
Lymphoblastic Leukemia, Lymphoblastic Leukemia in Children
CD19-Directed Chimeric Antigen Receptor (CAR) T-Cell Therapy for Relapsed/Refractory B-Lineage Leukaemia / Lymphoma - A Feasibility Protocol
The purpose of this study is to describe feasibility of delivering point-of-care manufactured CD19-directed CAR T-cell therapy to patients with relapsed/ refractory B-lineage leukaemia/ lymphoma.
- Conditions
- Lymphoblastic Leukemia, Lymphoblastic Leukemia in Children, Lymphoblastic Leukemia, Acute Adult, B-cell Acute Lymphoblastic Leukemia
- Trial name
- NCT05648019
- Testing
- Anti-CD19 CAR T-cells
- Where
- 2 sites in Singapore
- Volunteers
- 40 people
- Sponsor
- KK Women's and Children's Hospital
Arsenic Trioxide, Childhood ALL
South China Children Cancer Group - Relapsed-Acute Lymphoblastic Leukemia 2022 Protocol
In recent years, the prognosis of pediatric relapsed ALL patients has improved, but the 5-year OS of patients with first recurrence is still less than 50%.
- Trial name
- SCCCG-R-ALL (NCT05682131)
- Testing
- Realgar Indigo naturalis formula, Conventional chemotherapy
- Where
- China
- Volunteers
- 210 people
- Sponsor
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
T-cell Acute Lymphoblastic Leukemia/Lymphoma
Clinical Study of Senl-T7 CAR T Cells in the Treatment of Relapsed and Refractory CD7+ Acute T-ALL/T-LBL
This is an open, prospective, dose-escalation clinical study to evaluate the safety and efficacy of Senl-T7 in patients with relapsed or refractory CD7+ acute T lymphoblastic leukemia or T lymphoblastic lymphoma.Meanwhile, PK/PD…
- Trial name
- NCT05626400
- Testing
- Senl-T7
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Hebei Senlang Biotechnology Inc., Ltd.
T Lymphoblastic Leukemia/Lymphoma
CD7 CAR-T Cells in T-cell Lymphoma/Leukemia
T-cell lymphoma/leukemia is a group of highly lethal diseases with a high relapse rate and poor prognosis. CD7 was proved to be widely expressed in T-cell malignant, which makes it a promising therapeutic target.
- Trial name
- NCT05620680
- Testing
- CD7 CAR-T cells
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Shenzhen University General Hospital
Acute Myeloid Leukemia in Remission, Myelodysplastic Syndromes
Allogeneic Hematopoietic Cell Transplantation From HLA-matched Donor After Flu-Mel-PTCy Versus Flu-Mel-ATG Reduced-intensity Conditioning
The present project aims at comparing two conditioning regimens (FM-PTCy vs FM-ATG). The hypothesis is that one or the two regimens will lead to a 2-year cGRFS rate improvement from 30% (the cGRFS rate with FM without ATG/PTCy)…
- Conditions
- Acute Myeloid Leukemia in Remission, Myelodysplastic Syndromes, Chronic Myeloid Leukemia in Remission, Myeloproliferative Syndrome
- Trial name
- HLA (NCT03852407)
- Testing
- Thymoglobulin, Melphalan, Fludarabine
- Where
- 10 sites in Belgium
- Volunteers
- 114 people
- Sponsor
- University of Liege
Diffuse Large B Cell Lymphoma, Chronic Lymphocytic Leukemia
Safety and Efficacy of KRT-232 in Combination With Acalabrutinib in Subjects With R/R DLBCL or R/R CLL
This study evaluates KRT-232, a novel oral small molecule inhibitor of MDM2, combined with acalabrutinib for the treatment of adults with Diffuse Large B-Cell Lymphoma and Chronic Lymphocytic Leukemia.
- Conditions
- Diffuse Large B Cell Lymphoma, Chronic Lymphocytic Leukemia, Non Hodgkin Lymphoma
- Trial name
- NCT04502394
- Testing
- KRT-232, acalabrutinib
- Where
- 45 sites in United States, Australia and 9 more
- Volunteers
- 84 people
- Sponsor
- Kartos Therapeutics, Inc.
Acute Lymphoblastic Leukemia
Treatment of Breakpoint Cluster Region-Abelson (BCR-ABL) Negative ALL in Adults
After consolidation therapy adult patients (≥18 yr) with Ph-negative ALL will be treated with continuation chemotherapy or allogeneic hematopoietic stem cell transplantation (alloHSCT) according to both measurable residual…
- Trial name
- NCT04179929
- Testing
- Pediatric-type of chemotherapy, allogeneic HSCT
- Where
- 108 sites in Spain
- Volunteers
- 300 people
- Sponsor
- PETHEMA Foundation
Acute Myeloid Leukemia, Non-hodgkin's Lymphoma
CD 70 CAR T for Patients With CD70 Positive Malignant Hematologic Diseases
A Study of CD 70 CAR T for patients with CD70 positive malignant hematologic diseases
- Conditions
- Acute Myeloid Leukemia, Non-hodgkin's Lymphoma, Multiple Myeloma
- Trial name
- NCT04662294
- Testing
- CD70 CAR T-cells
- Where
- China
- Volunteers
- 108 people
- Sponsor
- Zhejiang University
B-cell Acute Lymphoblastic Leukemia, B-cell Childhood Acute Lymphoblastic Leukemia
Blinatumomab After TCR Alpha Beta/CD19 Depleted HCT
This trial will assess the feasibility of alpha/beta T-cell and B-cell depleted allogeneic hematopoietic cell transplantation (HCT) followed by blinatumomab therapy for high-risk B cell acute lymphoblastic leukemia (ALL) as a…
- Conditions
- B-cell Acute Lymphoblastic Leukemia, B-cell Childhood Acute Lymphoblastic Leukemia, B-Cell ALL, Childhood
- Trial name
- NCT04746209
- Testing
- Alpha/Beta T-cell and B-cell depleted HCT, Blinatumomab
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Medical College of Wisconsin
Lymphoblastic Leukemia, Acute, Childhood, Lymphoblastic Leukemia
CARTALL: Chimeric-Antigen Receptor (CAR) T-Cell Therapy for Relapsed/ Refractory T-Lineage Acute Lymphoblastic Leukaemia
The objective of this study is to assess the safety and efficacy of anti-CD7 CAR T-cells in patients with refractory or relapsed T-lineage acute lymphoblastic leukemia (T-ALL).
- Conditions
- Lymphoblastic Leukemia, Acute, Childhood, Lymphoblastic Leukemia, Lymphoblastic Leukemia, Acute Adult, Lymphoblastic Leukemia in Children
- Trial name
- NCT05043571
- Testing
- CAR T-cell therapy
- Where
- Singapore
- Volunteers
- 20 people
- Sponsor
- National University Hospital, Singapore
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
A Pilot Study on Intermittent Ibrutinib in Patients With Advanced-phase Chronic Lymphocytic Leukemia (CLL)
Ibrutinib, an inhibitor of Bruton´s tyrosine kinase (BTK) is approved in CLL as continuous, daily administration of 420 mg orally until progression.
- Trial name
- IbruOnOff (NCT04771507)
- Testing
- Ibrutinib
- Where
- 9 sites in Norway, Sweden
- Volunteers
- 50 people
- Sponsor
- Jeanette Lundin